ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

OXN Oxonica

3.125
0.00 (0.00%)
17 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxonica LSE:OXN London Ordinary Share GB00B0D09P49 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.125 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Statement re Licence and Patent

05/09/2008 12:39pm

UK Regulatory


    RNS Number : 8535C
  Oxonica plc
  05 September 2008
   


    5 September 2008

    Oxonica plc

    Second statement regarding Licence and Patent Dispute with Neuftec Limited


    Oxonica plc ("Oxonica") a leading international nanomaterials group, today issues the following statement in connection with the licence
and patent dispute between its wholly owned subsidiary Oxonica Energy Limited ("Energy") and Neuftec Limited ("Neuftec"), a company
registered in the Commonwealth of Dominica.

    On July 12th 2007 Oxonica issued a statement that Neuftec had confirmed that Envirox* sourced from Nyacol (the form of Envirox*
currently sold by Oxonica) does not come within the scope of its granted European patent in the UK (EP(UK)1299508) and that the only issue
remaining was the interpretation of the wording of the licence agreement and whether royalties are due on Envirox* sales up to the date the
licence agreement was terminated.

    The case regarding the interpretation of the licence agreement was heard in the High Court, London on 11TH June 2008. In the judgment of
Deputy Judge Peter Prescott QC handed down today it was found that royalties are payable to Neuftec on Envirox* under the licence agreement
when it was in force. There will shortly be a further hearing regarding the royalties payable, the payment of costs and permission to
appeal. Oxonica has previously provided for £408k based on its estimate of Envirox* royalties that may be payable. Oxonica has been advised
by its legal advisors that it has good grounds for an appeal, which it is currently considering.  

    For further information, please contact:

    Oxonica plc                                               01865 856 700
    Kevin Matthews, Chief Executive
    Richard Clarke, Finance Director

    The Broadcast PR Business                       0207 7469 4036
    Matthew Locke


    Notes to Editors

    About Oxonica plc - www.oxonica.com

    Oxonica (AIM: OXN.L) is one of the leading international nanomaterials groups with products already launched into international markets
and is listed in London on the AIM market. It was spun-out from Oxford University in 1999. Oxonica's mission is to focus on the development
of innovative commercial solutions for international markets using its expertise in the design and application of nanomaterials. It owns a
portfolio of demand driven products that offer substantial benefits to the target markets of energy, materials, security and diagnostics.

    The Group currently has four operating businesses: Oxonica Energy, Oxonica Materials, Oxonica Security and Oxonica Diagnostics. Oxonica
has already launched products into international markets. Lead products include:
    *     Envirox* fuel combustion catalyst - a catalyst improving fuel economy and reducing emissions
    *     Optisol* UV absorber - a revolutionary photostable UV protection system designed to optimise the performance of quality sunscreens
and anti-premature aging products

    Oxonica is also active in searching for the next generation of products and is already engaged in developing transformational detection
technologies which will enable a new generation of ultrasensitive multiplex diagnostic tools for the clinical diagnostic life science and
security markets. In addition, Oxonica is developing other UV absorber technologies into polymer systems and coatings, based on similar
technologies to that used in Optisol*.



This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
STRFKPKNDBKDOCK

1 Year Oxonica Chart

1 Year Oxonica Chart

1 Month Oxonica Chart

1 Month Oxonica Chart